You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity

Alerts

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
886 Combined allogeneic NK cell and Herzuma® is effective in HER2-low breast cancer preclinical model by enhancing antibody-dependent cellular cytotoxicity
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address